Research Progress on Predictive Biomarkers of Immunotherapy Efficacy in Non-small Cell Lung Cancer

TL;DR

This paper reviews biomarkers that predict how well immunotherapy works for non-small cell lung cancer patients.

Contribution

The paper provides a comprehensive review of recent advances in predictive biomarkers for immunotherapy in NSCLC.

Findings

Only a minority of NSCLC patients benefit long-term from immunotherapy.

Molecular biology and genomic sequencing have enabled the discovery of new predictive biomarkers.

Understanding the tumor and immune microenvironment is key to identifying effective biomarkers.

Abstract

肺癌是世界上最常见的恶性肿瘤之一，其中非小细胞肺癌（non-small cell lung cancer, NSCLC）占大多数。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的出现极大地改变了NSCLC的治疗策略，并改善了患者预后，然而现实中只有少部分患者能够获得长期受益。因此，确定可靠的预测生物标志物对选择治疗方式至关重要。随着近年来分子生物学、基因组测序技术的发展以及对肿瘤及其宿主免疫微环境的认识不断深入，生物标志物的研究层出不穷。本文围绕NSCLC免疫治疗疗效的预测生物标志物进行综述，以期为精准免疫治疗提供指导。